Pharmaceuticals company Mankind Pharma announced Q1FY26 results Revenue from Operations at Rs 3,570 crore, up by 24.5% YoY. Domestic revenue at Rs 3,101 crore, up 18.9%, Exports at Rs 469 crore, up 81.1% YoY. EBITDA margin of 23.8% up by 20 bps YoY and PAT margin of 12.5%. Diluted EPS of Rs 10.6 down by 20.1% YoY (FV Re 1). Rajeev Juneja, Vice Chairman & Managing Director, said: “Mankind’s revenue grew by 24.5% with EBITDA margins at 23.8% in Q1FY26 led by continued 1.4x outperformance in Chronic, strong growth in Consumer segment and BSV consolidation. Visible encouraging trends with 1.8x volume growth to IPM led by outperformance in Anti-infectives & Respiratory segment – apart from continued outperformance in Cardiology and Anti Diabetics. BSV growth initiatives are making steady progress and we remain confident of delivering healthy performance this year onwards. As we celebrate 30 years of our operations, we would like our shareholders to be part of this milestone therefore the Company’s Board has approved an interim dividend of Rs 1 per share.” Result PDF
Conference Call with Mankind Pharma Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Mankind Pharma announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Revenue from Operations at Rs 3,079 crore, up by 27% YoY Domestic revenue at Rs 2,544 crore, up 18% YoY, Exports at Rs 535 crore, up 100% YoY Adjusted EBITDA margin of 23.1% down by 120 bps YoY and PAT margin of 13.9% Diluted EPS of Rs 10.3 down by 12.5% YoY (FV Re.1) FY25 Financial Highlights: Revenue from Operations at Rs 12,207 crore, up by 19% YoY Domestic revenue at Rs 10,675 crore, up 13% YoY, Exports at Rs 1,532 crore, up 88% YoY Adjusted EBITDA margin of 25.9% up by 130 bps YoY and PAT margin of 16.4% Diluted EPS of Rs 49.1, up by 3% YoY (FV Re.1) Rajeev Juneja – Vice Chairman & Managing Director said, “Mankind’s revenue grew by 27% with adjusted EBITDA margins at ~23% in Q4 FY25 led by continued 1.3x outperformance in Chronic, strong growth in Consumer segment and BSV consolidation. In FY25, reported revenue growth was 19% with adj. EBITDA margin of ~26% This has been a transformative year at Mankind with several strategic initiatives to ensure higher productivity and outperform IPM as seen in the past. BSV integration is progressing well with key focus on R&D;, improving MR productivity & scaling mandate brands across domestic & International business. During FY25, we’ve laid a strong foundation to deliver long-term sustainable growth led by four key pillars - steady base business, fast growing specialty chronic, high potential OTC business, and high entry barrier super specialty portfolio of BSV.” Result PDF